术后甲状腺球蛋白作为放射性碘治疗的标尺:欧洲多中心1317例分化型甲状腺癌患者决策树分析
该研究基于欧洲多中心1317例分化型甲状腺癌患者,采用条件推断树模型,以年龄、性别、组织学、T分期、N分期、风险分层、残留估计、TSH和Tg预测治疗后全身显像结果。N阳性患者中Tg>23.3 ng/mL者转移概率为83%;N阴性患者按Tg进一步分为三个风险亚组。模型交叉验证稳定可重复,可用于指导术后131I给药及筛选需根治性而非辅助性131I治疗的患者。
要点
- N阳性患者中,Tg>23.3 ng/mL者治疗后全身显像提示转移的概率为83%。
- N阴性患者根据Tg值进一步分为三个不同风险率的亚组。
- 决策树模型在交叉验证中保持稳定可重复,可指导术后131I治疗决策。
核心结论
- 开发了一个简单稳健的决策树模型,能可靠提供术后持续/转移性分化型甲状腺癌的概率信息。
- 该信息可指导术后131I给药,并筛选需要根治性而非辅助性131I治疗方案的患者。
研究设计与样本
- 欧洲多中心系列,纳入1317例分化型甲状腺癌患者。
- 将年龄、性别、组织学、T分期、N分期、风险分层、残留估计、TSH和Tg作为潜在预测因子,纳入条件推断树(ctree)回归算法,开发预测治疗后全身显像(PT-WBS)结果的风险分层模型。
主要发现
- N分期将人群分为N阳性与N阴性两个亚组。
- N阳性患者中,Tg>23.3 ng/mL者转移性疾病概率为83%,高于Tg较低者。
- N阴性患者根据Tg值进一步分为三个不同风险率的亚组。
- 模型在交叉验证迭代过程中保持稳定可重复。
关键数值与推荐
- N阳性患者中,Tg>23.3 ng/mL对应的转移概率为83%。
临床怎么用
- 术后决策树模型可提供持续/转移性分化型甲状腺癌的概率信息,以指导术后131I给药。
- 该模型可筛选需要根治性而非辅助性131I治疗方案的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: An accurate postoperative assessment is pivotal to inform postoperative 131I treatment in patients with differentiated thyroid cancer (DTC). We developed a predictive model for post-treatment whole-body scintigraphy (PT-WBS) results (as a proxy for persistent disease) by adopting a decision tree model. METHODS: Age, sex, histology, T stage, N stage, risk classes, remnant estimation, TSH, and Tg were identified as potential predictors and were put into regression algorithm (conditional inference tree, ctree) to develop a risk stratification model for predicting the presence of metastases in PT-WBS. RESULTS: The lymph node (N) stage identified a partition of the population into two subgroups (N-positive vs N-negative). Among N-positive patients, a Tg value > 23.3 ng/mL conferred a 83% probability to have metastatic disease compared to those with lower Tg values. Additionally, N-negative patients were further substratified in three subgroups with different risk rates according to their Tg values. The model remained stable and reproducible in the iterative process of cross validation. CONCLUSIONS: We developed a simple and robust decision tree model able to provide reliable informations on the probability of persistent/metastatic DTC after surgery. These information may guide post-surgery 131I administration and select patients requiring curative rather than adjuvant 131I therapy schedules.
引用
- Giovanella L, Milan L, Roll W, et al. Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 37121981. doi:10.1007/s00259-023-06239-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。